TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II

• Status: Not yet recruiting
• Trial end date: 2033-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to improve upon the TINI study treatment. The study will test the ability of a type of immunotherapy called blinatumomab to clear persistent leukemia. Blinatumomab targets CD19 which is located on the leukemia cells outer membrane.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Stanford University
• Collaborators: Amgen; Lucile Packard Children's Hospital Foundation; Pediatric Oncology Experimental Therapeutics Investigators' Consortium
• Treatments: Asparaginase; Blinatumomab; Bortezomib; Dexamethasone; Mercaptopurine; Methotrexate; Mitoxantrone; Pegaspargase; Vorinostat

Criteria

Inclusion Criteria:

• Patient is ≤ 365 days of age at the time of diagnosis.

• Patient has newly diagnosed CD19 positive acute lymphoblastic leukemia (ALL) or acute undifferentiated leukemia with ≥25% blasts in the bone marrow (M3), with or without extramedullary disease. Patients with CD19 positive biphenotypic acute leukemia are eligible. Patients with CD19 positive mature B-cell ALL that carry a KMT2Ar are eligible.

• Limited prior therapy, including hydroxyurea for 72 hours or less, systemic glucocorticoids for one week or less, cytarabine for 72 hours or less, one dose of vincristine, and one dose of intrathecal chemotherapy.

• Written informed consent following Institutional Review Board, NCI, FDA, and OHRP Guidelines.

Exclusion Criteria:

• Patients with prior therapy, other than therapy specified in inclusion criteria.

• Patients with mature B-cell ALL that does not have a KMT2Ar or patients with acute myelogenous (AML) or T-cell ALL.

• Patients with Down syndrome.

• Inability or unwillingness of legal guardian/representative to give written informed consent